A gene therapy induced emphysema model and the protective role of stem cells by unknown
Zarogoulidis et al. Diagnostic Pathology 2014, 9:195
http://www.diagnosticpathology.org/content/9/1/195RESEARCH Open AccessA gene therapy induced emphysema model and
the protective role of stem cells
Paul Zarogoulidis1*, Wolfgang Hohenforst-Schmidt2, Haidong Huang3, Despoina Sahpatzidou4, Lutz Freitag5,
Leonidas Sakkas6, Aggeliki Rapti7, Ioannis Kioumis1, Georgia Pitsiou1, Kokkona Kouzi-Koliakos8, Anna Papamichail6,
Antonis Papaiwannou1, Theodora Tsiouda9, Kosmas Tsakiridis10, Konstantinos Porpodis1, Sofia Lampaki1,
John Organtzis1, Andreas Gschwendtner11 and Konstantinos Zarogoulidis1Abstract
Background: Chronic obstructive pulmonary disease presents with two different phenotypes: chronic bronchitis
and emphysema with parenchymal destruction. Decreased expression of vascular endothelial growth factor and
increased endothelial cell apoptosis are considered major factors for emphysema. Stem cells have the ability of
vascular regeneration and function as a repair mechanism for the damaged endothelial cells. Currently, minimally
invasive interventional procedures such as placement of valves, bio-foam or coils are performed in order to improve
the disturbed mechanical function in emphysema patients. However, these procedures cannot restore functional
lung tissue. Additionally stem cell instillation into the parenchyma has been used in clinical studies aiming to
improve overall respiratory function and quality of life.
Methods: In our current experiment we induced emphysema with a DDMC non-viral vector in BALBC mice and
simultaneously instilled stem cells testing the hyposthesis that they might have a protective role against the
development of emphysema. The mice were divided into four groups: a) control, b) 50.000 cells, c) 75.000 and
d) 100.000 cells.
Results: Lung pathological findings revealed that all treatment groups had less damage compared to the control
group. Additionally, we observed that emphysema lesions were less around vessels in an area of 10 μm.
Conclusions: Our findings indicate that stem cell instillation can have a regenerative role if applied upon a tissue
scaffold with vessel around.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_195
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by chronic inflammation and progressive
destruction of lung parenchyma. Currently there are no
interventions able to reverse or even stop disease pro-
gression. Transplantation is the only option to regain
functional tissue. Full medical treatment and smoking
cessation are able to slow the progression of emphysema,
improve quality of life and prolong survival [1]. Surgical* Correspondence: pzarog@hotmail.com
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article, unless otherwise stated.lung volume reduction reduces hyperinflation and im-
proves overall functional status although lung tissue is
sacrificed. This approach is considered feasible for patients
with predominantly upper lobe emphysema. In order to
avoid surgery, minimally invasive interventional bronchos-
copy techniques have been developed. The application of
endobronchial valves, coils and bio-foam have been re-
cently added as arrows in the quiver for emphysema treat-
ment [2-4]. Despite all pharmaceutical or interventional
treatment modalities the loss of lung tissue and remo-
deling continues [5,6]. Chronic obstructive pulmonary
disease involves airways of all generations, the alveoli
(<2 mm) and the tissue beyond. The major dysfunctionntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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due to the loss of elastic lung recoil. Furthermore; endo-
thelial dysfunction and vascular remodeling are initiated
by vascular endothelial growth factor (VEGF)-mediated
apoptosis [7]. Inflammatory response is also initiated by
exposure to environmental factors such as; air pollution
and cigarette smoking. Key factors in the destructive
cascades are proteolytic substances and oxidant stress
[8,9]. The irreversible process is further accelerated by
frequent exacerbations. Despite the removal of the trig-
ger factor, the inflammatory cells (neutrophils, macro-
phages and lymphocytes) still remain in large numbers
within the respiratory airways and stimulate inflamma-
tion, remodeling and destruction, due to nature of the
continuous exposure [10,11]. The airway epithelium has
slow proliferative and renewal capability, unless injured
[12]. While differentiated cells cannot compensate for
the loss of complex lung tissue destroyed by the above
outline processes, stem cells may have these capabilities.
Stem cells have the ability of self-renewal and through
trophic units they are mobilized and attracted to the site
of damage [13]. Stem cells can be classified according to
their potency to differentiate, in: unipotent stem cells,
able to produce only one cell type, multipotent cells able
to form all cells of one particular lineage, pluripotent
stem cells capable of differentiating into any of the
embryonic germ layers [14]. Finally, there are totipotent
cells that can give rise to an entire organism. This prop-
erty is retained in mammals by the zygote and up to at
least 4-cell stage embryo [15-17].
Stem cells are also classified in embryonic stem cells
and adult (ASCs) or non embryonic stem cells. The
pluripotent embryonic stem cells derived from the inner
cell mass of the blastocyst have the unique capacity to
generate any cell of the body. Additionally they can stay
as undifferentiated cell type for prolonged period of time
in culture [16,18,19]. Adult stem cells (ACSs) have self-
renewal capability, they are multipotent cells obtained
from adult tissues.
Because of their unique characteristics, self-renewing
and multilineage differentiation, stem cells and especially
mesemchymal stem cells MSCs, are promising candi-
dates for potential therapeutic uses in regenerative me-
dicine, cell-based therapy, dentistry and tissue engineering
[20,21]. Stem cells plasticity and regeneration ability
has rend them a great promise for the treatment of a
variety of diseases such as cardiovascular diseases, heart
failure, diabetes, liver diseases, stroke, Parkinson’s and
Huntinghton disease and cirrhosis [20,22,23]. More-
over; they poses the ability to modulate immune system
responses by modulating the immunosuppressive effect
of B and T lymphocytes and therefore they have been
used as a possible treatment for autoimmune diseases,
systemic sclerosis rheumatoid arthritis, systemic lupuserythematosus, and autoimmune encephalomyelitis [24-26].
Currently, many research labs conduct animal and human
studies investigating the protective effect of stem cells in
the lung parenchyma [27-34]. We had recently developed
an animal model of induced lung emphysema by a non-
viral vector DDMC [35]. In the present study we investi-
gated whether adult stem cells administered by a sprayer
probe after emphysema induction might have a protective




The non-viral vector was purchased from Ryujyu science
corporation, Seto-City, Japan by PZ and WHS under the
contract EG179806600JP. The non-viral vector has the
following characteristics; fast and easy procedure, stable
for autoclaving sterilization at 121°C for 15 minutes,
broad peak performance, applicable in high-throughput-
screening (HTS), no serum inhibition, broad cell line
range, best results with siRNA applications, excellent
reproducibility, low toxicity in comparison with DEAE-
dextran, high efficiency by use of low DNA amounts, a
high DNase protection facility by DNase degradation.
Encouraged by our previous results [35] we chose this
vector for this stem cell study.
Animals
Eighty BALBC mice age 7–8 weeks old, purchased from
the “Theageneio” Anticancer Hospital. The Institute has
the following authorization for production and experi-
mentation of mice EL 25 BIO 011 and EL 25 BIO 013.
The protocol was authorized by the Aristotle University
of Thessaloniki. The mice included were isolated (1 per
cage) in a temperature-controlled room on 12-hour light–
dark cycle and were allowed free access to food and water.
The 80 mice were divided in four groups receiving differ-
ent amounts of stem cells: a) control group (only non viral
vector administration), b) 50.000 stem cells plus non-
viral vector, c) 75.000 stem cells plus non-viral vector, d)
100.000 stem cells plus non-viral vector.
Protocol
The vector was delivered in 1 ml and was diluted with
10 ml of 5% glucose solution (11 ml solution in total),
as previously published [35]. The mixture was vortexed
gently in order to homogenize. A Sunmist® compressor
nebulizer (6 liters/minute and 35 psi) was used to aero-
solize 1 ml/11 ml in 5 minutes for each mouse (Figure 1).
Each subject received 1 ml prior to stem cell instillation.
The size distribution of the solution droplets was de-
termined using a Malvern Mastersizer 2000 laser scatte-
ring apparatus (Malvern, Worcestershire, UK) equipped
with a Scirocco module (Malvern, Worcestershire, UK)
Figure 1 Jet-Nebulizer sunmist with a residual cup of maximum
load 10 ml.
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to be sprayed directly into the sample chamber, normal
to the laser beam. A refractive index of 1.33 was used
for the dispersed phase. A minimum of three repetitions
were held for each treatment. The mass median aero-
dynamic diameter was 3.9 μm. It has to be noted that
the dilution directions were followed as indicated by
the company Ryujyu Science, however; a different neb-
ulization system was used. We administered nebulisa-
tion of 4–10 ml 5% glucose solution with an ultrasound
device (2 MHz) over a period of 15–30 min. The aero-
sol was delivered to the lungs of the mice in a nose only
sealed plastic cage. Details can been found in our previ-
ous publication [35].Figure 2 Equipment Mastersizer 2000 for aerosol droplet measuremeStem cells
Human Umbilical Cord Mesenchymal Cells (HUCMCs)
isolated from Wharton’s Jelly was provided by Biohellenika
Biotechnology Company. HUCMCs were plated in 6-well
plates (BD Falcon) and cultured in Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine serum,
penicillin (100 IU/ml) and streptomycin (100 μg/ml).
HUCMCs were grown to 60% confluency and then,
transfected with 5 μg of DNA mixture encoding SB100x
transponase and pT2-Venus-neo transposon expression
plasmids (1:9 ratio). Transfection was performed using
Xfect™ reagent (Clontech), according to the manufac-
turer’s instructions. HUCMCs stably expressing both
the fluorescent Venus and antibiotic-resistance neo genes
were selected using 0.5 mg/ml G418. The stem cells were
administered with an Olympus® spray catheter (with
Stylet) PW-6C-1 (working channel 1050 mm and mini-
mum channel size 2.mm). Two syringes were used; a)
insulin (100unit loading) and b) 10 ml loading (Figure 3).
For this protocol we used three groups; a) 50.000 cells,
b) 75.000 cells and c) 100.000 cells.
Pathology and imaging technique
Sections of 4 microns of lung tissue samples were cut
using freezing microtome (Leica CM1900). A polarized
light microscope (Zeiss) was used to examine unstained
lung tissue sections on glass slides.
Moreover; the lung tissues were placed in labeled plasic
cassettes and after overnight 18 hour schedule using an
automatic tissue processor (Thermo Scientific Wxcelsior,
ES Histokinette) sections of 4–5 microns were cut from
paraffin blocks using a microtome (MICROM, HM340E).
All the sections were stained with the heamatoxylin and
eosin method.
Results and discussion
In order to properly evaluate the effect of the non-viral
vector to the lung parenchyma and the effect of the stem
cells in different concentrations we sacrificed animals at
the following time points. At the end of the first week of
the experiment (Figure 4), second week (Figure 5) andnt.
Figure 3 Equipment for stem cell instillation (Olympus stylet probe). Black arrow represents the syringe with the stem cells, yellow arrow
represents the syringe working as the air inflator, red arrow represents the probe that enters the mouse airway and the blue arrow represents the
metallic stylet within the probe which assists in the efficient deposition of the probe within the trachea of the mice.
Figure 4 Pathology specimen after stem cell administration.
7 days after the first administration; A) control group, B) 50.000
stem cell group, C) 75.000 stem cell group and D) 100.000 stem
cell group.
Figure 5 Pathology specimen after stem cell administration.
14 days after the first administration; A) control group, B) 50.000
stem cell group, C) 75.000 stem cell group and D) 100.000 stem
cell group.
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Figure 7 White arrows indicate stem cells within alveoli.
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cell application) (Figure 6). We also present evidence
with Figure 7 where the stem cells are displayed with
fluorescence in dark background, the stem cells are
within the alveoli, providing clear evidence that they
distributed efficiently with our methodology. Our patholo-
gical findings indicate that the non-viral vector induced
emphysema as previously [35] and that the higher the
concentration of the instilled stem cells >50.000 cell popu-
lation the lower the emphysema lesions observed. The
stem cells did not reconstruct in any case alveoli or other
type of tissue within the lung parenchyma, however; it
seems that they acted as an anti-inflammatory factor.
Conclusions
Chronic obstructive pulmonary disease and emphysema
are known to be associated with air pollution and smok-
ing habit [36]. COPD and emphysema reduce the respi-
ratory capability of the subject and induce lung injury
which in several situations are life threatening [37]. Cur-
rently several drugs such as inhaled bronchodilators,
inhaled corticosteroids, phosphodiesterase-4 inhibitors
and mucolytics are used as symptomatic therapy and
blockage of inflammation [38-40]. Other drugs such as
macrolides have been also used for control of COPD ex-
acerbations by exploiting their anti-inflammatory pro-
perties [41]. It has been observed that during COPD
exacerbation the circulating endothelial stem cells are
not decreased, however; their population is abnormally
high, probably during an effort for tissue repair and in-
flammation control [42,43]. Increased levels of vascular
endothelial growth factor (VEGF) have been associated
with increased levels of circulating endothelial stem cells
[43]. It has been previously observed that mesenchymal
stem cells protect cigarette smoke lung injury, by up-Figure 6 Pathology specimen after stem cell administration.
21 days after the first administration; A) control group, B) 50.000
stem cell group, C) 75.000 stem cell group and D) 100.000 stem
cell group.regulating vascular endothelial growth factor receptor 2
and tumor growth factor β-1, and down-regulating
inflammatory response, cell apoptosis and excessive pro-
tease expression [27]. In laboratory model experiments,
mesenchymal stem cells have been co-cultured with
scaffolds. Producing functional parts of the respiratory
system, provided evidence that these cells might be used
for tissue repair in the airways [44]. The same observa-
tion has been made for other diseases of the respiratory
system such pulmonary fibrosis, cystic fibrosis and pul-
monary hypertension [45]. In vivo imaging of these cells
has been previously accomplished during airway regen-
eration in mice [30]. It has been also shown that bone
marrow cells could repair cigarette induced emphysema
[28,46]. The same observation was made for stem cells
derived from the adipose tissue [47]. However; there is
an ongoing investigation regarding another stem cell
population such as the bronchioalveolar stem cells, and
how this population affects the initiation of a respiratory
disease and whether it can reverse it [48]. Other resear-
ches use basal stem cells and investigate their role in
epithelial homeostasis and remodeling [49]. Activation
of satellite cells in the intercostals muscles has been also
proposed as an additional method of assisting the res-
piratory function of COPD patients [50]. Based on previ-
ously presented data, clinical studies have been started,
evaluating the potential tissue repair ability of stem cells
by administering them in patients with copd [28,29,31].
Early results indicate that the stem cell administration is
safe and that the respiratory function can be improved.
Currently this treatment lacks of pathological evidence
of whether it can truly regenerate alveoli units, or whe-
ther the improvement of the respiratory function is due
to the anti-inflammatory property. It has been previously
proposed that mesenchymal stem cells have the ability
to regenerate tissue [51]. Even if these cells had unlim-
ited capabilities, the main problem of an in vivo tissue
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new healthy and functioning alveoli as in our case, or re-
pair damaged ones. There are several possible approaches.
One could create a scaffold with an extracellular matrix
guiding stem cells to create the desired structure or one
could bioengineer stem cell with the genetic information
to create alveoli. Possibly a disease by disease case should
be investigated. In our experiment we provide a novel
model of emphysema. We found no pathological evidence
that under these conditions, stem cells would create new
alveoli tissue or any other structure of the respiratory sys-
tem. However; image analysis proved that the stem cells
assisted in down-regulating the inflammation of the trig-
ger factor (DDMC non-viral vector). Lipopolysaccharides
have been also recently used to induce emphysema [52].
The anti-inflammatory effect has been previously ob-
served in other studies [27]. Major limitations of our study
were firstly the lack of inflammatory marker evaluation
however; tissue damage is observed to be inversely asso-
ciated with the administration of Human Umbilical Cord
Mesenchymal Cells (HUCMCs) population. Secondly we
did not evaluate the survival of the groups, however; our
objective was to present solid data (pathological) whether
stem cells regenerate any kind of tissue formation within
the lung parenchyma when a lung injury trigger factor
exists. Moreover; we did not evaluate the population of
stem cells deposited per mm2 of alveoli. It was impossible
to know exactly the population of the stem cells instilled
in the lungs and hoe of them were deposited in the alveoli
since the mice in several occasions exhaled the stem cell
compound due to cough. Additionally, less damage to the
alveoli was observed next to vessels (<10 μm) probably,
because as previously observed these cells are attract by
vascular endothelial growth factors [53].
In our current work we investigated the protective ef-
fect of adult Human Umbilical Cord Mesenchymal Cells
(HUCMCs) in a gene therapy induced emphysema model.
We observed that any dosage from ≥50.000cells has a pro-
tective effect. The observation that we find most interest-
ing is that around the vessels of the lung parenchyma in an
area of no more than 10 μm the emphysema lesions were
significantly reduced. Our conclusion based on patholo-
gical findings is that vessels transport the regenerative cells
and are diffused through the vascular wall to the regional
tissue and that a kind of scaffold is necessary for the stem
cells to regenerate lung parenchyma constructions.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PZ and WHS conceived the experiment. LS, AP and AG performed the
pathological analysis. HH provided useful insights regarding the vector. KKK
provided the stem cells. AP, AR, TS, SL, JO, IK, GP, KT, KP and DS performed
the experiements. KZ and LF provided useful insights. All authors read and
approved the final manuscript.Acknowledgments
Informed consent was obtained by the Biohellenika company for their usage
in the experiment. The authors would like to thank Antonios Sakkas,
Anastasios Kallianos, Kaid Darwiche and Aggeliki Baliaka for their assistance
and support throughout the experiment.
Author details
1Pulmonary Department, “G. Papanikolaou” General Hospital, Aristotle
University of Thessaloniki, Thessaloniki, Greece. 2II Medical Department,
“Coburg” Regional Department, University of Wuerzburg, Coburg, Germany.
3Department of Respiratory Diseases, Changhai Hospital/First Affiliated
Hospital of the Second Military Medical University, Shanghai, China.
4Experimental Animal Laboratory, “Theiageneio” Anticancer Hospital,
Thessaloniki, Greece. 5Department of Interventional Pneumology,
Ruhrlandklinik, West German Lung Center, University Hospital, University
Duisburg-Essen, Essen, Germany. 6Pathology Department, “G. Papanikolaou”
General Hospital, Thessaloniki, Greece. 7Pulmonary Department, “Sotiria”
Hospital of Chest Diseases, Athens, Greece. 8Department of Histology
Embryology, School of Medicine, Aristotle University of Thessaloniki,
Thessaloniki, Greece. 9Internal Medicine Department, “Thegenio” Anticancer
Hospital, Thessaloniki, Greece. 10Cardiothoracic Surgery Department, Saint
“Luke” Private Hospital, Thessaloniki, Panorama, Greece. 11Pathology
Department, Hospital of Amberg, Amberg, Germany.
Received: 13 June 2014 Accepted: 7 October 2014References
1. Postolache P, Cojocaru DC: Pulmonary rehabilitation–from guidelines to
practice. Rev Med Chir Soc Med Nat Iasi 2013, 117:380–387.
2. Barua A, Vaughan P, Wotton R, Naidu B: Do endobronchial valves improve
outcomes in patients with emphysema? Interact Cardiovasc Thorac Surg
2012, 15:1072–1076.
3. Herth FJ, Eberhard R, Gompelmann D, Slebos DJ, Ernst A: Bronchoscopic
lung volume reduction with a dedicated coil: a clinical pilot study.
Ther Adv Respir Dis 2010, 4:225–231.
4. Falkenstern-Ge RF, Ingerl H, Kohlhaufl M: Severe emphysema treated by
endoscopic bronchial volume reduction with lung sealant (AeriSeal).
Case Rep Pulmonol 2013, 2013:361391.
5. Elbehairy AF, Webb KA, Alberto Neder J, O’Donnell DE: Should mild COPD
be treated? Evidence for early pharmacological intervention. Drugs 2013,
73:1991–2001.
6. Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J: Impact of
patients’ satisfaction with their inhalers on treatment compliance
and health status in COPD. Respir Med 2014, 108(2):358–365.
doi:10.1016/j.rmed.2013.09.021. Epub 2013 Oct 2.
7. Siafakas NM, Antoniou KM, Tzortzaki EG: Role of angiogenesis and vascular
remodeling in chronic obstructive pulmonary disease. Int J Chron
Obstruct Pulmon Dis 2007, 2:453–462.
8. Shapiro SD: Proteinases in chronic obstructive pulmonary disease.
Biochem Soc Trans 2002, 30:98–102.
9. MacNee W: Pulmonary and systemic oxidant/antioxidant imbalance in
chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:50–60.
10. Curtis JL, Freeman CM, Hogg JC: The immunopathogenesis of chronic
obstructive pulmonary disease: insights from recent research. Proc Am
Thorac Soc 2007, 4:512–521.
11. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS,
Timens W: Effect of 1-year smoking cessation on airway inflammation in
COPD and asymptomatic smokers. Eur Respir J 2005, 26:835–845.
12. Kotton DN, Summer R, Fine A: Lung stem cells: new paradigms.
Exp Hematol 2004, 32:340–343.
13. Lajtha LG: Stem cell concepts. Differentiation 1979, 14:23–34.
14. Nor JE: Tooth regeneration in operative dentistry. Oper Dent 2006,
31:633–642.
15. Mitalipov S, Wolf D: Totipotency, pluripotency and nuclear
reprogramming. Adv Biochem Eng Biotechnol 2009, 114:185–199.
16. Fortier LA: Stem cells: classifications, controversies, and clinical
applications. Vet Surg 2005, 34:415–423.
17. Mavroudi M, Zarogoulidis P, Porpodis K, Kioumis I, Lampaki S, Yarmus L,
Malecki R, Zarogoulidis K, Malecki M: Stem cells’ guided gene therapy of
Zarogoulidis et al. Diagnostic Pathology 2014, 9:195 Page 7 of 7
http://www.diagnosticpathology.org/content/9/1/195cancer: new frontier in personalized and targeted therapy. J Cancer Res
Ther (Manch) 2014, 2:22–33.
18. Keller G: Embryonic stem cell differentiation: emergence of a new era in
biology and medicine. Genes Dev 2005, 19:1129–1155.
19. Tuch BE: Stem cells–a clinical update. Aust Fam Physician 2006,
35:719–721.
20. Baksh D, Song L, Tuan RS: Adult mesenchymal stem cells:
characterization, differentiation, and application in cell and gene
therapy. J Cell Mol Med 2004, 8:301–316.
21. Nadig RR: Stem cell therapy - hype or hope? A review. J Conserv Dent
2009, 12:131–138.
22. Patel DM, Shah J, Srivastava AS: Therapeutic potential of mesenchymal
stem cells in regenerative medicine. Stem Cells Int 2013, 2013:496218.
23. Kim N, Cho SG: Clinical applications of mesenchymal stem cells. Korean J
Intern Med 2013, 28:387–402.
24. Cipriani P, Carubbi F, Liakouli V, Marrelli A, Perricone C, Perricone R, Alesse E,
Giacomelli R: Stem cells in autoimmune diseases: implications for
pathogenesis and future trends in therapy. Autoimmun Rev 2012,
12:709–716.
25. Cipriani P, Di Benedetto P, Liakouli V, Del Papa B, Di Padova M, Di Ianni M,
Marrelli A, Alesse E, Giacomelli R: Mesenchymal stem cells (MSCs) from
scleroderma patients (SSc) preserve their immunomodulatory properties
although senescent and normally induce T regulatory cells (Tregs) with
a functional phenotype: implications for cellular-based therapy. Clin Exp
Immunol 2013, 173:195–206.
26. Cipriani P, Marrelli A, Benedetto PD, Liakouli V, Carubbi F, Ruscitti P, Alvaro S,
Pantano I, Campese AF, Grazioli P, Screpanti I, Giacomelli R: Scleroderma
Mesenchymal Stem Cells display a different phenotype from healthy
controls; implications for regenerative medicine. Angiogenesis 2013,
16:595–607.
27. Guan XJ, Song L, Han FF, Cui ZL, Chen X, Guo XJ, Xu WG: Mesenchymal stem
cells protect cigarette smoke-damaged lung and pulmonary function partly
via VEGF-VEGF receptors. J Cell Biochem 2013, 114:323–335.
28. Ribeiro-Paes JT, Bilaqui A, Greco OT, Ruiz MA, Marcelino MY, Stessuk T, de
Faria CA, Lago MR: Unicentric study of cell therapy in chronic obstructive
pulmonary disease/pulmonary emphysema. Int J Chron Obstruct Pulmon
Dis 2011, 6:63–71.
29. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP: A placebo-
controlled, randomized trial of mesenchymal stem cells in COPD. Chest
2013, 143:1590–1598.
30. Kim JK, Vinarsky V, Wain J, Zhao R, Jung K, Choi J, Lam A, Pardo-Saganta A,
Breton S, Rajagopal J, Yun SH: In vivo imaging of tracheal epithelial cells
in mice during airway regeneration. Am J Respir Cell Mol Biol 2012,
47:864–868.
31. Hackett TL, Knight DA, Sin DD: Potential role of stem cells in management
of COPD. Int J Chron Obstruct Pulmon Dis 2010, 5:81–88.
32. Zarogoulidis P, Kontakiotis T, Zarogoulidis K: Inhaled gene therapy in lung
cancer: “as for the future, our task is not to foresee it, but to enable it”.
Ther Deliv 2012, 3:919–921.
33. Zarogoulidis P, Darwiche K, Sakkas A, Yarmus L, Huang H, Li Q, Freitag L,
Zarogoulidis K, Malecki M: Suicide gene therapy for cancer - current
strategies. J Cancer Res 2014, 2(1):22–33.
34. Zarogoulidis P, Darwiche K, Hohenforst-Schmidt W, Huang H, Li Q, Freitag L,
Zarogoulidis K: Inhaled gene therapy in lung cancer: proof-of-concept for
nano-oncology and nanobiotechnology in the management of lung
cancer. Future Oncol 2013, 9:1171–1194.
35. Zarogoulidis P, Hohenforst-Schmidt W, Darwiche K, Krauss L, Sparopoulou
D, Sakkas L, Gschwendtner A, Huang H, Turner FJ, Freitag L, Zarogoulidis K:
2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral
vector: still a long way toward the safety of aerosol gene therapy.
Gene Ther 2013, 20:1022–1028.
36. Goldkorn T, Filosto S, Chung S: Lung Injury and Lung Cancer Caused
by Cigarette Smoke-Induced Oxidative Stress: Molecular Mechanisms
and Therapeutic Opportunities Involving the Ceramide Generating
Machinery and Egf Receptor. Antioxid Redox Signal 2014, Epub ahead
of print.
37. Angelis N, Porpodis K, Zarogoulidis P, Spyratos D, Kioumis I, Papaiwannou A,
Pitsiou G, Tsakiridis K, Mpakas A, Arikas S, Tsiouda T, Katsikogiannis N,
Kougioumtzi I, Machairiotis N, Argyriou M, Kessisis G, Zarogoulidis K: Airway
inflammation in chronic obstructive pulmonary disease. J Thorac Dis
2014, 6:S167–S172.38. Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q, Cortijo J: Roflumilast
N-oxide reverses corticosteroid resistance in neutrophils from patients
with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2014,
134(2):314–322.
39. Ulrik CS: Clinical benefit of fixed-dose dual bronchodilation with
glycopyrronium and indacaterol once daily in patients with chronic
obstructive pulmonary disease: a systematic review. Int J Chron Obstruct
Pulmon Dis 2014, 9:331–338.
40. Kew KM, Dias S, Cates CJ: Long-acting inhaled therapy (beta-agonists,
anticholinergics and steroids) for COPD: a network meta-analysis.
Cochrane Database Syst Rev 2014, 3:CD010844.
41. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K:
Macrolides: from in vitro anti-inflammatory and immunomodulatory
properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol
2012, 68:479–503.
42. Caramori G, Rigolin GM, Mazzoni F, Leprotti S, Campioni P, Papi A:
Circulating endothelial stem cells are not decreased in pulmonary
emphysema or COPD. Thorax 2010, 65:554–555.
43. Sala E, Villena C, Balaguer C, Rios A, Fernandez-Palomeque C, Cosio BG,
Garcia J, Noguera A, Agusti A: Abnormal levels of circulating endothelial
progenitor cells during exacerbations of COPD. Lung 2010, 188:331–338.
44. Cha HJ, Hwang ES: Current status of biology, bioengineering, and
therapeutic potential of stem cells. Arch Pharm Res 2012, 35:193–196.
45. Roomans GM: Tissue engineering and the use of stem/progenitor cells
for airway epithelium repair. Eur Cell Mater 2010, 19:284–299.
46. Huh JW, Kim SY, Lee JH, Lee JS, Van Ta Q, Kim M, Oh YM, Lee YS, Lee SD:
Bone marrow cells repair cigarette smoke-induced emphysema in rats.
Am J Physiol Lung Cell Mol Physiol 2011, 301:L255–L266.
47. de Faria CA, de las Heras Kozma R, Stessuk T, Ribeiro-Paes JT: Experimental
basis and new insights for cell therapy in Chronic Obstructive Pulmonary
Disease. Stem Cell Rev 2012, 8:1236–1244.
48. Kim CF: Paving the road for lung stem cell biology: bronchioalveolar
stem cells and other putative distal lung stem cells. Am J Physiol Lung Cell
Mol Physiol 2007, 293:L1092–L1098.
49. Rock JR, Randell SH, Hogan BL: Airway basal stem cells: a perspective on
their roles in epithelial homeostasis and remodeling. Dis Model Mech
2010, 3:545–556.
50. Martinez-Llorens J, Casadevall C, Lloreta J, Orozco-Levi M, Barreiro E,
Broquetas J, Gea J: [Activation of satellite cells in the intercostal muscles
of patients with chronic obstructive pulmonary disease]. Arch Bronconeumol
2008, 44:239–244.
51. Foronjy RF, Majka SM: The potential for resident lung mesenchymal stem
cells to promote functional tissue regeneration: understanding
microenvironmental cues. Cells 2012, 1:874.
52. Kobayashi S, Fujinawa R, Ota F, Angata T, Ueno M, Maeno T, Kitazume S,
Yoshida K, Ishii T, Gao C, Ohtsubo K, Yamaguchi Y, Betsuyaku T, Kida K,
Taniguchi N: A single dose of lipopolysaccharide into mice with
emphysema mimics human chronic obstructive pulmonary disease
exacerbation as assessed by micro-computed tomography. Am J Respir
Cell Mol Biol 2013, 49:971–977.
53. Karathanasis V, Petrakis S, Topouridou K, Koliakou E, Koliakos G, Demiri E:
Intradermal injection of GFP-producing adipose stromal cells promotes
survival of random-pattern skin flaps in rats. Eur J Plast Surg 2013,
36:281–288.
doi:10.1186/s13000-014-0195-7
Cite this article as: Zarogoulidis et al.: A gene therapy induced
emphysema model and the protective role of stem cells. Diagnostic
Pathology 2014 9:195.
